News | March 30, 2015

Medicines Company Receives European Commission Approval for Cangrelor and Raplixa Sealant Powder

Marketing authorization for antiplatelet agent and blood clotting mixture valid in 31 countries of the European Economic Area

March 30, 2015 — The Medicines Company announced that the European Commission has granted marketing authorization for two acute care products – Kengrexal (cangrelor) and Raplixa (sealant powder). These approvals follow the issuance of positive opinions in January by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The marketing authorization for each of these products is now valid in the 31 countries of the European Economic Area (EEA), which includes all 28 European Union (EU) Member States, plus Norway, Iceland and Liechtenstein.

Kengrexal is a bioavailable, quickly reversible intravenous small molecule antiplatelet agent to prevent platelet activation and aggregation that leads to thrombosis in the acute care setting, including in patients undergoing percutaneous coronary intervention (PCI). Raplixa is a mixture of two essential blood clotting proteins, fibrinogen and thrombin, formulated as a unique dry powder topical hemostatic product.

Prof. Philippe Gabriel Steg, M.D., director of the Coronary Care Unit, Hôpital Bichat-Claude Bernard, Paris, France, stated, “The availability of a potent, injectable, and reversible antiplatelet agent will be an important adjunct to our therapeutic armamentarium to reduce peri-procedural complications and help make PCI safer. It will be useful in a variety of settings from acute myocardial infarction to elective PCI, mostly in patients in whom antiplatelet agents have either not been administered or are known to be poorly effective.”

Prof. Wolf O. Bechstein, M.D., Ph.D., professor of surgery, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany, noted, “I am pleased to see that Raplixa is approved throughout Europe. We were very fond of the product during the Phase 3B trial and look forward to using it in everyday practice. This will be an important new and innovative product for us to use in hemostasis treatment.”

The company used a centralized regulatory procedure, which allows applicants to obtain authorization for marketing throughout the EU, subject to national pricing and reimbursement processes. “Some member states such as England will allow marketing immediately,” said Stephanie Plent, M.D., executive vice president and chief value officer, The Medicines Company. “Other countries require pricing and reimbursement to be negotiated first, and that process is underway.”

Commercialization of each product will be directed by the company’s Global Innovation Groups, with European coordination via the company’s Zurich-based offices. The company will also begin finalizing logistics for product packaging and distribution channels for Europe. In addition, the company anticipates partnering with leading firms in Europe to provide the necessary field-based educational and promotional resources at a national and/or regional level.

A new drug application for Kengrexal (cangrelor) and a biologics license application for Raplixa are under active review by the U.S. Food and Drug Administration.

For more information: www.themedicinescompany.com

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Overlay Init